Limjindaporn Thawornchai, Panaampon Jutatip, Malakar Shilu, Noisakran Sansanee, Yenchitsomanus Pa-Thai
Department of Anatomy, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Department of Anatomy, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Biochem Biophys Res Commun. 2017 Jan 29;483(1):58-63. doi: 10.1016/j.bbrc.2017.01.006. Epub 2017 Jan 5.
Dengue virus is the causative agent of dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. High rates of dengue virus replication and virion production are related to disease severity. To identify anti-DENV compounds, we performed cell-based ELISA testing to detect the level of DENV E protein expression. Among a total of 83 inhibitors, eight were identified as inhibitors with antiviral activity. Epidermal growth factor receptor inhibitor II (EGFR/ErbB-2/ErbB-4 inhibitor II) and protein tyrosine phosphatase inhibitor IV (PTP inhibitor IV) significantly inhibited dengue virus production and demonstrated low toxicity in hepatocyte cell lines. Our results suggest the efficacy of tyrosine kinase/phosphatase inhibitors in decreasing dengue virus production in HepG2 cells.
登革病毒是登革热、登革出血热和登革休克综合征的病原体。登革病毒的高复制率和病毒粒子产生与疾病严重程度相关。为了鉴定抗登革病毒化合物,我们进行了基于细胞的ELISA检测以检测登革病毒E蛋白表达水平。在总共83种抑制剂中,有8种被鉴定为具有抗病毒活性的抑制剂。表皮生长因子受体抑制剂II(EGFR/ErbB-2/ErbB-4抑制剂II)和蛋白酪氨酸磷酸酶抑制剂IV(PTP抑制剂IV)显著抑制登革病毒产生,并在肝细胞系中显示出低毒性。我们的结果表明酪氨酸激酶/磷酸酶抑制剂在降低HepG2细胞中登革病毒产生方面的有效性。